Adcetris® (brentuximab vedotin) plus novel immunotherapy combination delivers 100% progression free survival at 12 months in phase 2 trial of patients with early stage classical hodgkin lymphoma

Bothell, wash.--(business wire)-- #ash23--seagen inc. (nasdaq: sgen) today announced that clinically meaningful progression-free survival (pfs), a secondary endpoint, was observed in a phase 2 study evaluating the antibody-drug conjugate (adc) adcetris® (brentuximab vedotin) in combination with the pd-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (an+ad) as first-line treatment for early and advanced stage classical hodgkin lymphoma (chl). this is the first time 12-m.
SGEN Ratings Summary
SGEN Quant Ranking